Improving the Design of Future PCI Trials for Stable Coronary Artery Disease: JACC State-of-the-Art Review.

Abstract

The role of percutaneous coronary interventions in addition to medical therapy for patients with stable coronary artery disease continues to be debated in routine clinical practice, despite more than 2 decades of randomized controlled trials. The residual uncertainty arises from particular challenges facing revascularization trials. Which endpoint do doctors care about, and which do patients care about? Which participants should be enrolled? What background medical therapy should we use? When is placebo control relevant? In this paper, we discuss how these questions can be approached and examine the merits and disadvantages of possible options. Engaging multiple stakeholders, including patients, researchers, regulators, and funders, to ensure the design elements are methodologically valid and clinically meaningful should be an aspirational goal in the development of future trials.

• Authors: Guillaume Marquis-Gravel, David J Moliterno, Darrel P Francis, Peter Jüni, Yves D Rosenberg, Bimmer E Claessen, Robert J Mentz, Roxana Mehran, Donald E Cutlip, Cynthia Chauhan, Susan Quella, Faiez Zannad, Shaun G Goodman
• Journal: Journal of the American College of Cardiology (J Am Coll Cardiol) Vol. 76 Issue 4 Pg. 435-450 (07 28 2020) ISSN: 1558-3597 [Electronic] United States
• PMID: 32703515 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Review)
• Copyright: Copyright © 2020 American College of Cardiology Foundation. All rights reserved.

Topics

• Coronary Artery Disease (surgery)
• Humans
• Percutaneous Coronary Intervention (methods)
• Quality Improvement
• Randomized Controlled Trials as Topic (methods, standards)
• Research Design